US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Vistagen

< Previous 1 2 3 Next >
News headline image
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Participate in Upcoming Investor Conferences
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Appoints Nick Tressler as Chief Financial Officer
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Participate in Stifel Healthcare Conference 2025
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Appoints Paul Edick to its Board of Directors
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Present at The Menopause Society 2025 Annual Meeting
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Present at the BTIG Virtual Biotechnology Conference
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
Tickers VTGN
News headline image
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
From Vistagen
Via Business Wire
Tickers VTGN
< Previous 1 2 3 Next >